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Abstract
Introduction: There are substantial variabilities of the clinical characteristics and outcomes 
of severe coronavirus disease (COVID-19) creating difficulty to do an optimal assessment of 
this condition. We reviewed the current English literature to quantify the findings of baselines 
characteristics and health outcomes of patients with severe COVID-19 primarily with acute 
respiratory distress syndrome (ARDS).
Methods: We examined only studies that assessed patients with proven COVID-19 by RT-
PCR by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with at least one of 
the following severity criteria: severe COVID-19, treated in the ICUs, ARDS and/or invasive 
mechanical ventilation (IMV) treatment. We assessed the quality of the studies according to the 
National Heart, Lung and Blood Institute, Study Quality Assessment Tools.
Results: Seven of 39 studies fulfilled the inclusion criteria. These seven studies included a total 
1,863 patients, the median age was 63.5 years (49-70). A total 370 (19.8%) were females. Four 
studies were from the USA, two from China and one from Italy. Comorbidities were reported 
in six studies. Fever was reported in five studies and it was present in 159 out of 272 patients. 
Cough and shortness of breath (SOB) were reported in four studies, they were present in 111 
out of 142 and 100 out of 142 of patients respectively. The median of total lymphocytes was re-
ported in five studies with a range of 400 – 889/ul. IMV ranged from 15% to 100% and mortality 
ranged from 14.6% to 88%. In a subgroup analysis by countries, patients from the US showed 
more comorbidities, higher percent of IMV and mortality. The assessment quality score of the 
seven studies was (5), for a total score of (8).
Conclusions: Severe COVID-19 was predominantly seen in male patients who were 60 years 
and older associated with comorbidities. Most of the patients were admitted at the ICU, needed 
IMV support due to ARDS and had a mortality range of 14.6-88%.
Introduction
The new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of 
the coronavirus disease-19 (COVID-19) and it was originally reported in Wuhan, China 
in December 2019. Today this unprecedented COVID-19 pandemic spread to the whole 
globe resulting in about 7,500,000 infected people and the loss of about 430,000 humans 
lives. [1] In relation to the severity of illness, COVID-19 has a spectrum of clinical pre-
sentations. Severe COVID-19 has been reported in about 14 % of patients with a fatality 
rate of 49%. [2] In the time of severe COVID-19 leading to an unexpectedly high number 
of deaths, it is important to examine history to reassure our best approaches to a new 
problem. Though severe COVID-19 is new for us, similar epidemics happened over time. 
In this regard, the historical quote the “Captain of the Men of Death” which was origi-
nally coined by John Bunyan for tuberculosis is very timely and wise to relate to severe 
COVID-19. [3] It is tempting to conceive that COVID-19 is the current Captain of Death.
It is important to highlight the exponential health care burden, morbidity, and mortality 
of severe COVID-19. The American Hospital Association estimates a total four-month 
financial impact of $202.6 billion in losses for America’s hospitals and health systems, or 
an average of $50.7 billion per month. [4] The UN’s Trade and Development Agency says 
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the slowdown in the global economy caused by the coronavirus outbreak is likely to cost at least $1 trillion. [5] 
There are substantial variabilities of the clinical characteristics and outcomes of severe COVID-19, which creates diffi-
culty in doing an optimal assessment of this condition. Though severe COVID-19 has been reported to present as septic 
shock, acute cardiac complication, stroke and involving many other organs; there is increasing evidence that the lung 
involvement resulting in ARDS is the most common and fatal complication. [6] The objective of the study is to review 
the current English literature to quantify the findings of clinical presentation and health outcomes of patients with 
severe COVID-19 primarily with acute respiratory distress syndrome (ARDS).  
Methods
Database Search Strategies 
We did a search in PubMed and Google Scholar using the queries “COVID-19”, “Severe COVID-19”, “Clinical Charac-
teristics” and “Clinical Outcomes”. 
Inclusion Criteria
Studies that assessed patients with proven COVID-19 by RT-PCR for SARS-CoV-2. These studies examined and pro-
vided data of patients with severe COVID-19, patients treated in the ICUs, patients with the diagnosis of ARDS and 
patients who were receiving treatment with invasive mechanical ventilation. 
Exclusion Criteria
Studies that did not include cases according to the inclusion criteria. Studies that claimed including cases according to 
our inclusion criteria, but they did not provide baseline clinical characteristics and outcomes.
Quality Assessment: We assessed the quality of the studies according to the National Heart, Lung and Blood Insti-
tute, Study Quality Assessment Tools. [7]
Results
Selected publications
Our search in the databases PubMed and Google Scholar revealed 39 publications. A total 32 publications were exclud-
ed according to the exclusion criteria and we selected eight publications for our review. Subsequently, a publication 
that reported assessing severe COVID-19 was eliminated because the reported findings were not consistent with severe 
COVID-19. This study reported A-a gradient for the non-severe and severe COVID-19 of 3.9 vs. 4.0 respectively. These 
reported severe cases showed a rate of ARDS of 15.6%, intensive care unit (ICU) admission of 19.1% and a mortality of 
8.1%. This clearly indicates that most of these cases were not severe COVID-19. [8] Therefore, there were seven publi-
cations for our review. [2,9-14]  
Total severe COVID-19 cases included by gender and age
Our study included a total 1,863 patients, the median age was 63.5 years and range was 49- 70 years. A total 370 (19.8%) 
were females. Four studies were from the USA, two from China and one from Italy. [2,9-14]
Reported comorbidities 
The comorbidities reported in six studies were as follows: diabetes mellitus 254 (13.6%), arterial hypertension 604/1818 
(33.2%), chronic obstructive pulmonary disease (COPD) 58/1779 (3.3%), chronic kidney disease (CKD) 51/1636 (3.1%). 
Clinical symptoms
Fever was reported in five studies and it was reported to be present in 159 out of 272 patients included in the five stud-
ies. Cough and shortness of breath (SOB) were reported in four studies. In these four studies, cough was present in 111 
out of 142 patients and SOB in 100 out of 142. None of the study reported vomiting and diarrhea.
Laboratory studies
The median of total lymphocytes was reported in five studies with a range of 400 – 889/ul. The arterial partial pressure 
of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio was reported in three studies with a range of 69-492 (median 
160).  
Imaging studies
Imaging studies were reported only in four studies. Bilateral lung infiltrates in chest X-ray were reported in 161 out 
of 188 (85.6%) patients and ground-glass opacities (GGO) on computerized tomography (CT) in 15 out of 45 patients 
(33.3%). 
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Studies Clinical Characteristics Outcomes
Grasselli et al.10
Journal. JAMA
Number of patients. 1,591 
Severity Criteria. ICU admission 
Country. Italy
Median age 63 years
Female 18%






Number of patients. 21 
Severity Criteria. ICU admission
Country. USA
Median age 70 years 
Female 48%
DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 
47.6%
Fever 52%, SOB 76%
Total lymphocyte 889/ul 
PaO2/FiO2 ratio 169





Number of patients. 24
Severity Criteria. ICU admission 
Country. USA
Mean age 64 +/- 18 (23-97) years
Female 38%
DM 58%, CKD 21%, COPD 4%
Fever 50%, SOB 88%
Total lymphocytes 720/ul
CXR lung infiltrates 100%, CT GGO 80%
Mortality 50%
IMV 75%
Huang et al.13                   
Journal. Lancet
Number of patients. 13
Severity Criteria. ICU admission 
Country. China
Median age 49 years 
Female 15%
DM 8%, HTN 15%, COPD 8%, CVD 23%
Fever 100%, SOB 92%
Total lymphocytes 400/ul D-dimer 2.4 mg/L








Wu et al.2           
Journal. JAMA IM
Number of patients. 84 
Severity Criteria. ARDS 
Country. China
Median age 58.5 years 
Female 28.6%
DM 19%, HTN 27.4%








Goyal et al.14                 
Journal. NEJM
Number of patients. 130 
Severity Criteria. IMV 
Country. USA
Median age 64.5 years
Female 29.2%
DM 27.7%, HTN 70 53.8%, COPD 5.4%
Fever 34.6%
CXR lung infiltrates 87.7%
Mortality 14.6%
Richardson et al.9                
Journal. JAMA
Number of patients. 373
Severity Criteria. ICU admission 
Country. USA
Total lymphocytes 800/ul *Mortality 88% IMV 320/373, 
85.7%
Table 1. Baseline Characteristics and Outcomes of Patients with Severe COVID
Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CHF, congestive 
heart failure;  CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, 
C-reactive protein; CT, computerized tomography; CVD, cardiovascular disease; CXR, chest x-ray; DM, 
diabetes mellitus; GGO, ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive 
mechanical ventilation; NIMV, noninvasive mechanical ventilation; PaO2/FIO2, arterial partial pressure of 
oxygen/fraction of inspired oxygen; SOB, shortness of breath. *Mortality in IMV 282/320, 88%
Outcomes
Baseline outcomes are depicted in Table 1. 
Comparison of baseline clinical characteristics and outcomes in patients from USA and China.
To find out whether the type of medical practice and patient population by country could have influenced the clinical 
characteristics and outcomes, we compared the cases of severe COVID-19 by country. In this comparison, patients re-
ported in the US showed more comorbidities more often, higher percent of IMV and mortality than those from China 
(Table 2a and Table 2b). 
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Table 2b. Baseline Characteristics and Outcomes of Patients with Severe COVID-19 from Studies from 
China.
Abbreviations: CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; CT, computerized tomography; CXR, chest x-ray; DM, diabetes mellitus; GGO, 
ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical ventilation; 
PaO2/FIO2, arterial partial pressure of oxygen/fraction of inspired oxygen; SOB, shortness of breath.
Studies Clinical Characteristics Outcomes
Arentz et al.11                        
Journal. JAMA
Number of patients. 21
Severity Criteria. ICU admission 
Country. USA
Median age 70 years 
Female 48%
DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 47.6%
Fever 52%, SOB 76%
Total lymphocyte 889/ul 
PaO2/FiO2 ratio 169
CXR lung infiltrates 52%, b/l GGO 48%
Mortality 52.4%
IMV 71%
Bhatraju et al.12 
Journal. NEJM
Number of patients. 24
Severity Criteria. ICU admission 
Country. USA
Mean age 64 +/- 18 (23-97) years
Female 38%
DM 58%, CKD 21%, COPD 4%
Fever 50%, SOB 88%
Total lymphocytes 720/ul
CXR lung infiltrates 100%, CT GGO 80%
Mortality 50%
IMV 75%
Goyal et al.14            
Journal. NEJM
Number of patients. 130 
Severity Criteria. IMV 
Country. USA
Median age 64.5 y 
Female 29.2%
DM 27.7%, HTN 70 53.8%, COPD 5.4%
Fever 34.6%
CXR lung infiltrates 87.7%
Mortality 14.6%
Richardson et al.9              
Journal. JAMA
Number of patients. 373 
Severity Criteria. ICU admission
Country. USA
Total lymphocytes 800/ul *Mortality 88%
IMV 320/373, 85.7%
Table 2a. Baseline Characteristics and Outcomes of Patients with Severe COVID-19 from Studies from 
USA.
Studies Clinical Characteristics Outcomes
Huang et al.13                  
Journal. Lancet
Number of patients. 13 
Severity Criteria. ICU admission
Country. China
Median age 49 years Female 15%
DM 8%, HTN 15%, COPD 8%, CVD 23%
Fever 100%, SOB 92%
Total lymphocytes 400/ul D-dimer 2.4 mg/L








Wu et al. 2
Journal. JAMA IM 
Number of patients. 84 
Severity Criteria. ARDS 
Country. China
Median age 58.5 years Female 28.6%
DM 19%, HTN 27.4%
Fever 92.9%, SOB 59.5%, cough 81%






Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; COPD, chronic 
obstructive pulmonary disease; CRP, C-reactive protein; CVD, cardiovascular disease; CXR, chest x-ray; 
DM, diabetes mellitus; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical ventilation; 
NIMV, noninvasive mechanical ventilation; SOB, shortness of breath.
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/55 5
ULJRI Severe COVID-19






















1. Was the study question or objective clearly stated? 1 1 1 1 1 1 1
2. Was the study population clearly and fully described, 
including a case definition? 1 1 1 1 1 1 1
3. Were the cases consecutive? CD CD CD CD CD CD CD
4. Were the subjects comparable? NR NR NR NR NR NR NR
5. Was the intervention clearly described? NA NA NA l NA NA NA
6. Were the outcome measures clearly defined, valid, 
reliable, and implemented consistently across all study 
participants? 1 1 1 1 1 0 1
7. Was the length of follow-up adequate? 1 0 1 0 1 1 1
8. Were the statistical methods well- described? 1 0 1 1 0 0 1
9. Were the results well-described? 1 1 1 1 1 0 1
Yes=1 No =0 Other (CD, NR, NA)* Score: / 8 6 4 6 5 5 3 6
Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Assessment of data quality
The assessment of data quality score for the seven studies was five for a total score of eight (Table 3).
Discussion
Our study examined seven studies addressing severe COVID-19 with an average quality score of 5 out of 8 points. 
These seven studies showed a substantial variability of the clinical characteristics and outcomes of patients with se-
vere COVID-19. Severe COVID 19 was seen predominantly in males; six of the studies showed a range of 15% - 48% of 
females and an average of 29.5% female. [2,10-14] It means; less than 1 out of 5 patients with severe COVID-19 will be a 
woman. At the best interpretation of 4 out of 6 studies that provided the patients ages, the patients median age was 64 
years and older. [10-12,14] Six of the studies revealed multiple comorbidities. [2,10-14] Diabetes mellitus, arterial hyper-
tension and COPD were the most reported comorbidities. 
The angiotensin converting enzyme (ACE)-2 has been established to play an essential role in preventing the develop-
ment of the toxic inflammatory response in COVID-19. [15] Furthermore, ACE-2 was reported to decrease with aging 
and to have a lower expression in males. [16] The latter is related to the fact that the ACE-2 genes map to the X chromo-
some. [17] Similarly, ACE-2 is expressed less in patients with comorbidities. [15] In line with these specific distributions 
of the expression of the ACE-2, elderly male patients with comorbidities are expected to be the main patients with 
severe COVID-19 as reported by the studies in our review. 
An important finding of our review is that fever was not very common among patients with severe COVID-19. Fever 
was common in studies reported in China and these studies have a lower mortality. [2,13] This observation is in line 
with the statement that fever is a marker of optimal host response to an injury. Interestingly, some studies showed that 
fever was present in only about 50% of patients and the same studies revealed a mortality of about 50%. [2,13] It could 
be speculated that patients without fever were severely ill and had a poor host response resulting in death. 
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Lymphopenia is a common laboratory marker of severe COVID-19 and it is being considered a major factor in the patho-
genesis and mechanisms of the severity of COVID-19. [18] Severe COVID-19 has been associated with a cytokine release 
storm largely related to the ACE-2. The ACE-2 is found in many cells of different organs. ACE converts angiotensin-I 
into angiotensin-II, which through the angiotensin type-1 receptor (AT-1R), triggers vasoconstriction, inflammation, 
and thrombosis. [15] On the other hand, ACE-2 converts angiotensin II into angiotensin 1-7, which binds to angiotensin 
type 2 receptor (AT-2R) triggering vasodilation, less fibrosis and less thrombosis. Thus, ACE-2 is a master regulator of 
the renin-angiotensin system (RAS) by converting angiotensin I and angiotensin II to 1-9 and 1-7 respectively. Because 
ACE-2 is the receptor of SARS-CoV-2, upon the virus binds to ACE-2, the counter regulation activity of ACE-2 over 
renin-angiotensin system (RAS) is lost.
Our study has some weaknesses and strengths. Some of the weaknesses are related to the few numbers of studies, the 
quality of the studies, lack of standardization of baseline characteristics, and outcomes. All these factors resulted in an 
important variability of the characteristics and outcomes of patients with severe COVID-19. Many of the weaknesses 
are acceptable in view of the urgent need to report data of severe COVID-19. The strength of our review study is that 
according to our knowledge this is the first review study on severe COVID-19.
In conclusion, severe COVID-19 was predominantly seen in male patients aged 60 years and older associated mostly 
with diabetes mellitus, arterial hypertension, and COPD. Fever seems to be present in a half of the patients and more 
often SOB. Most of the patients were admitted at the ICU, needed IMV support due to ARDS and had a mortality range 
of 14.6-88%.
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